The Cancer Genome Atlas (TCGA) initiative, by generating comprehensive genomic characterization of diverse human cancers, poses the critical question of how genomic variation translates to cancer. Genomic abnormalities are thought to drive cancer phenotypes through their effects on proteins and proteomes, which can be analyzed by systematic application of new proteomic technologies. The National Cancer Institute (NCI) Clinical Proteomic Technology Assessment for Cancer (CPTAC) initiative has implemented standardized technology platforms in a biomarker development pipeline and, as one of the initial 5 CPTAC programs, we have made a major contribution to this effort. We have already pioneered this pipeline for cancer biomarker development through the Jim Ayers Institute for Precancer Detection and Diagnosis, a unique initiative established in the Vanderbilt-lngram Cancer Center. This application proposes the Vanderbilt Proteome Characterization Center (Vanderbilt PCC) built on the expertise and infrastructure of the Ayers Institute. The overall goal of the Vanderbilt PCC is to integrate genomic information with proteomic technologies to discover and verify protein biomarkers for cancer. To analyze genomically characterized tumor tissue biospecimens from the TCGA program, we will apply standardized liquid chromatography-tandem mass spectrometry (LC-MS/MS) and liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM-MS) platforms. These analyses will encompass global protein expression changes and changes in phosphorylated and acetylated proteins that regulate signaling networks in cancer. The Vanderbilt PCC will integrate TCGA-derived genomic data and other relevant information into the discovery process and develop systematic approaches to prioritize biomarker candidates. We will verify biomarker candidates in clinically relevant cohorts with standardized, targeted analyses. We will also advance technologies for assessment of signaling networks and functional subproteomes, the integration of genomic and proteomic data and the evaluation of analytical system performance. The Vanderbilt PCC brings to the CPTC network a fully integrated program with expertise in all of the critical areas specified by the RFA.
Cancer is characterized by abnormalities in genes, which are thought to cause disease by altering the content of tissue proteins and the functions they control. This project will use newly-developed technologies to link changes in tissue proteins to extensive new data on genetic abnormalities in tumors. The goal of the project is to identify protein characteristics that could serve as new diagnostics to aid the detection and treatment of cancer.
|Wang, Xiaojing; Zhang, Bing (2014) Integrating genomic, transcriptomic, and interactome data to improve Peptide and protein identification in shotgun proteomics. J Proteome Res 13:2715-23|
|Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704|
|Halvey, Patrick J; Wang, Xiaojing; Wang, Jing et al. (2014) Proteogenomic analysis reveals unanticipated adaptations of colorectal tumor cells to deficiencies in DNA mismatch repair. Cancer Res 74:387-97|
|Wang, Xia; Chambers, Matthew C; Vega-Montoto, Lorenzo J et al. (2014) QC metrics from CPTAC raw LC-MS/MS data interpreted through multivariate statistics. Anal Chem 86:2497-509|
|Whiteaker, Jeffrey R; Halusa, Goran N; Hoofnagle, Andrew N et al. (2014) CPTAC Assay Portal: a repository of targeted proteomic assays. Nat Methods 11:703-4|
|Johnson, Hannah; White, Forest M (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13:4581-93|
|Wang, Xiaojing; Liu, Qi; Zhang, Bing (2014) Leveraging the complementary nature of RNA-Seq and shotgun proteomics data. Proteomics 14:2676-87|
|Zhang, Bing; Wang, Jing; Wang, Xiaojing et al. (2014) Proteogenomic characterization of human colon and rectal cancer. Nature 513:382-7|
|Carr, Steven A; Abbatiello, Susan E; Ackermann, Bradley L et al. (2014) Targeted peptide measurements in biology and medicine: best practices for mass spectrometry-based assay development using a fit-for-purpose approach. Mol Cell Proteomics 13:907-17|
|Yang, Jing; Gupta, Vinayak; Carroll, Kate S et al. (2014) Site-specific mapping and quantification of protein S-sulphenylation in cells. Nat Commun 5:4776|
Showing the most recent 10 out of 21 publications